(UroToday.com) VEGF-targeting therapies have been shown to induce hypoxia in preclinical models of renal cell carcinoma (RCC), thus activating signaling through the hypoxia-inducible factors. In this phase 2 study, Dr. McDermott and colleagues tested the hypothesis that dual inhibition of both VEGF and downstream HIF signaling would provide anti-tumor for patients with clear cell RCC.